Emerald Clinics Ltd (ASX:EMD) CEO Dr Michael Winlo talks to Proactive about his company’s new partnership with Spectrum Biomedical UK to develop a real-world evidence data system in the UK. Shares in the company soared in response to the agreement which will see Emerald design and deliver an RWE asset focused on the safety and clinical outcomes for cannabis-based medicines produced by SBUK. The contract is valued at up to £400,000 (around A$723,000) with an initial fee of £150,000 for Emerald to start work on the project immediately.
Emerald Clinics makes first big move into UK with Spectrum Biomedical deal
Quick facts: Emerald Clinics Ltd
Price: 0.084 AUD
Market Cap: $17.76 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Emerald Clinics Ltd named herein, including the promotion by the Company of Emerald Clinics Ltd in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE